Bone Marrow & Stem Cell Transplant

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

A new trial reveals PTCy and abatacept significantly reduce chronic GVHD in stem cell transplant patients, offering promising outcomes over standard care.

A study reveals significant survival disparities in plasma cell leukemia, highlighting the benefits of stem cell transplantation for patient outcomes.

During a live event, Michael R. Bishop, MD, discussed a case of steroid-refractory GVHD and the efficacy and safety outcomes from the ROCKstar trial.

Research advances in blood cancer treatment enhance donor matching and reduce graft-vs-host disease, improving access to life-saving transplants for diverse patients.

With pegtarazimod and belumosudil advancing through the global pipeline, options are expanding for patients with GVHD worldwide.

New research identifies low counts of activated HLA-DR+CD3+ T cells as a potential biomarker for increased transplant-related mortality and severe chronic graft-versus-host disease.

During a live event, Michael R. Bishop, MD, discussed efficacy and safety outcomes from the AGAVE-201 trial.

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of outcomes for acute GVHD.

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and improving coping abilities.

A groundbreaking study enhances stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques.

FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options.

Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA approval on the horizon.

During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.

Ruxolitinib shows sustained efficacy and safety in treating steroid-refractory chronic graft-vs-host disease, outperforming standard therapies over three years.

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and axatilimab in patients with chronic graft-vs-host disease.

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.

A novel combination therapy shows high response rates in relapsed DLBCL, enhancing eligibility for autologous stem cell transplantation.

New trial data reveals cyclophosphamide plus cyclosporin significantly enhances GVHD prevention in stem cell transplant patients, offering hope for better outcomes.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.